Search
VolitionRX Ltd
VNRXAdd to Watchlist
0.847USD
-0.033-3.74%
Close 07-28 16:00（ET）Quotes delayed by 15 min
335.90KMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-27The current earnings forecast score of VolitionRX Ltd is 7.20, ranking 302 out of 386 in the Biotechnology & Medical Research industry. The average price target is 2.25, with a high of 5.00 and a low of 1.00.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
16.966
Target Price
+1596.60%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
VolitionRX Ltd
VNRX
5
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is VolitionRX Ltd's expected revenue for the next quarter?
VolitionRX Ltd's expected revenue is 482.67K.
What is VolitionRX Ltd's price target?
Analysts forecast that VolitionRX Ltd's price target is USD 2.25, with the highest forecast at USD 5.00 and the lowest forecast at USD 1.00.
How have VolitionRX LtdVNRX's recent earnings per share performed?
The market expectation was USD -0.97, while VolitionRX LtdVNRX's earnings per share (EPS) for the previous quarter was USD -1.04. EPS for the next quarter is expected at USD -0.57.
What is the analyst rating for VolitionRX Ltd?
Based on the ratings of VolitionRX Ltd's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.